Topic:

Emerging Markets

Latest Headlines

Latest Headlines

Chinese officials to shed some light on Glaxo probe at press briefing

What lies ahead for GlaxoSmithKline in China? The company has been waiting to find out since last summer, when investigators there charged it in a massive bribery scheme. But Glaxo may finally get some answers Wednesday, when Chinese police will brief the media about the drugmaker.

Lilly, Dobfar nailed with $450M fine, judge orders Brazilian plant closed

Eli Lilly in 2003 sold an antibiotics manufacturing plant in Cosmopolis, Brazil, to Italy's ACS Dobfar. But the fact that it has been more than a decade since Eli Lilly owned the facility has not kept the company from being ordered to pay $450 million to cover medical costs of dozens of plant employees for health problems they said came from exposure to hazardous materials.

China eases price controls over concerns of shortages

China, concerned about shortages of some commonly used drugs, has agreed to raise price caps it earlier set.

Covidien sets sights on Turkey with latest training outpost

Continuing its years-long effort to expand in emerging markets, Covidien has cut the ribbon on training center in Turkey, planning to educate local clinicians and amp up the demand for its products in the country.

Mindray Medical revenue jumps up by 9% in Q1

Revenues at China's Mindray Medical increased 9.4% year-over-year to $264.8 million in the first quarter.

Boehringer Ingelheim works a deal with Saudi firms to package its products

Boehringer Ingelheim is taking steps toward producing medicine in Saudi Arabia for the local market, striking a deal with two Saudi companies, Cigalah and Tabuk, which will manage and handle secondary packaging projects for 26 Boehringer Ingelheim products.

Harlan picks a partner and expands in Southeast Asia

Toxicology specialist Harlan Laboratories is looking to tap the growing market for contract research in Oceania, signing a deal with local outfit Invenium Pharmacology to do so.

Regulatory issues crush India's drug export growth

Faced with bans on some of its key drugmakers and intellectual property fights with Big Pharma, India has seen the worst pharma export numbers in a decade and a half.

WuXi poaches an AstraZeneca exec to amp up Chinese R&D

Chinese CRO WuXi PharmaTech has convinced Steve Yang, head of Asian R&D for AstraZeneca, to jump ship, joining the company as it looks to expand its presence in its home country and abroad.

Novartis' Alcon opens $160M plant in Singapore

With growing demand for eye drugs in Asia, Novartis' Alcon unit wants to have the capacity to sell into that market. To be able to do that, the company has opened a new plant in Singapore to make a variety of its eye drugs.